DELTA-Q-TECHNOLOGIES
2.5.2023 15:01:29 CEST | Business Wire | Press release
Delta-Q Technologies (Delta-Q), a leader in battery charging solutions for electric vehicles and industrial equipment, has announced that its innovative mid-power charger, the XV3300, is now in full-scale production. With its unique 3-in-1 design, this highly efficient charging system integrates a 3.3 kW battery charger, a 500 W DC-DC converter to power the vehicles’ auxiliary loads, and an EV charging station interface. These key features, encased in a ruggedized IP67 design, provide OEMs with an attractive package for simplifying electrification of their off-road applications.
“No other 3.3 kW charger on the market also includes a DC/DC converter for auxiliary DC loads and an EVSE charging interface in such a compact size,” said Mourad Chergui, Senior Product Manager with Delta-Q. “As we start full-scale production, we can begin to fulfill the substantial demand we received since we first announced the initial development.”
The 3.3 kW charging solution is available in 58.8, 65, and 120-volt DC models and is scalable, allowing OEMs to stack up to three chargers for power levels up to 10 kW. The XV3300 uses complex algorithms to deliver a precise charge to batteries of various chemistries and voltages, maximizing battery life and optimizing charge time.
Key features and benefits of the XV3300 charger include:
- High Reliability: The XV3300 battery charger is compact, rugged, and IP67-rated. It is tested for automotive-grade shock and vibration. Its fully sealed aluminum die-cast enclosure protects the charger from dust, liquids, and the effects of immersion in up to one meter of water.
- Enhanced Protection: The XV3300 is a low-voltage charger that optimally charges all battery chemistries and nominal voltages between 48 V to 120 V. It is also protected against short circuits, over-voltage, and over-temperature to ensure safe operation.
- Flexible Power Options: The XV3300 is scalable and can be paralleled to provide between 3.3 kW to 10 kW of power for faster-charging options. The charger is also available as an on-board and off-board charger, providing OEMs with additional flexibility.
- Integrated DC-DC converter: It provides auxiliary power to operate vehicle accessories such as air-conditioners, controllers, lights, turn signals, navigation, and communication devices. It also eliminates the need for an external DC-DC converter, saving OEMs and equipment operators space and cost.
- EV Charging Station Interface: The XV3300 complies with SAE J1772 (levels 1 and 2) and IEC 61851 (modes 2 and 3) to charge from standard EVSE AC charging stations across North America and Europe. This feature provides end-users more charging options and greater vehicle flexibility.
To register for updates on the XV3300 battery charger or for specific details, including product specifications, visit https://connect.delta-q.com/xv3300.
About Delta-Q Technologies
Delta-Q Technologies is charging the future and driving the world’s transition to electric energy. We collaboratively design, test, and manufacture robust battery chargers that improve the performance of our customers’ electric drive vehicles and industrial machines. As the supplier of choice for Tier 1 OEMs, our customer support and engineering expertise guide our customers through the electrification process for a sustainable world.
Delta-Q is part of the ZAPI GROUP of companies and headquartered in Vancouver, Canada. The team and distribution span five continents to service industries such as electric golf cars, lift trucks, aerial work platforms, e-mobility, floor care machines, utility/recreational vehicles, and new markets, like construction and outdoor power equipment. Please visit www.delta-q.com or follow company updates on LinkedIn for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom